Danaher completes Masimo Corporation acquisition

Danaher Corporation announced that it has completed the acquisition of Masimo Corporation.

Masimo’s trusted brand, advanced sensor technology and AI-enabled patient monitoring bring complementary and powerful new capabilities to the Danaher diagnostics portfolio. As a result of the transaction, Masimo is now a wholly-owned subsidiary of Danaher and Masimo common stock has ceased trading on the Nasdaq Stock Market. Masimo will continue to operate under the Masimo brand and will be a stand-alone operating company within Danaher’s Diagnostics segment.

“Masimo is a strong strategic fit for Danaher. Together, we expect to strengthen our ability to deliver differentiated products in acute care settings and accelerate Masimo’s growth and global reach,” said Julie Sawyer Montgomery, Executive Vice President of Diagnostics at Danaher. “We are excited to welcome the Masimo team to Danaher.”

The consideration payable to former Masimo stockholders will be paid in accordance with the terms of the merger agreement, as further described in the definitive transaction materials filed with the U.S. Securities and Exchange Commission.

Second quarter and full year 2026 outlook
There is no change to Danaher’s previously communicated second quarter and full-year 2026 guidance range, excluding the expected contribution from Masimo. The Company does not expect a material contribution from Masimo in the second quarter of 2026. The Company intends to update full-year 2026 guidance in connection with its second quarter earnings release to incorporate Masimo’s expected contribution.
MB Bureau